Are compounded GLP-1s legal in 2026? Honest answer: partly, conditionally, and less every quarter. The mass-market free-for-all that put cheap semaglutide copies on half the internet ended in 2025. What survives is a narrower legal lane — and a regulator actively working to close it.

The stakes are pure money. Brand-name GLP-1 pens list north of $1,000 a month before discounts, while compounded copies sell for $89 to $299 a month across telehealth sites, per third-party pricing reports. That gap is the entire reason this legal fight exists.

Compounding itself is legal and always has been. Federal law lets a licensed pharmacy mix a custom drug for a specific patient when an approved product cannot meet that patient’s needs — a child who needs a liquid version, an allergy to a dye. The FDA explains this in its compounding Q&A, and nothing about 2026 changed it.

What changed is the shortage exception. When the FDA lists a drug as in shortage, federal law lets pharmacies produce what the statute calls essentially a copy of it. Semaglutide and tirzepatide sat on the shortage list from 2022, and a multi-billion-dollar copy industry grew inside that gap.

Both shortages are over. The FDA declared tirzepatide resolved in October 2024 and semaglutide resolved on February 21, 2025. Mass-produced copies of Wegovy, Ozempic, Zepbound, and Mounjaro lost their legal cover in 2025 — with one narrow exception we cover below.

So the honest 2026 status: legal only as patient-specific compounding, under active FDA pressure, and not FDA-approved in any form. Every claim past that is marketing.

The Timeline: Every Date That Changed the Law

The whole fight fits in one table. Bookmark the last two rows — they are the live ones.

Date What happened Why it matters
Oct 2024 FDA declares tirzepatide shortage resolved Copy-making clock starts ticking
Feb 21, 2025 FDA declares semaglutide shortage resolved Same clock for semaglutide copies
Mar 5, 2025 Texas federal court denies compounders’ injunction on tirzepatide FDA deadlines stand
Mar 19, 2025 503B deadline: tirzepatide copies end Bulk tirzepatide era closes
Apr 22 / May 22, 2025 503A, then 503B semaglutide deadlines pass Mass semaglutide copying ends
Sep 2025 FDA announces warning letters to about 30 telehealth companies Marketing claims now enforcement targets
Feb 6, 2026 FDA says it will restrict GLP-1 raw ingredients for unapproved copies Supply chain squeeze begins
Apr 30, 2026 FDA proposes removing GLP-1s from the 503B bulks list Would end bulk compounding for good

The courtroom record matters here. The Outsourcing Facilities Association, a compounding trade group, sued to undo both shortage decisions — and a federal judge in the Northern District of Texas denied its injunction request on March 5, 2025 in the tirzepatide case, then denied the semaglutide request that spring, per court records reported by legal analysts. Appeals followed, but the deadlines held while they ran.

If you want the fuller backstory — how a 2022 supply crisis built a $1 billion-plus telehealth category in three years — read our guide to the GLP-1 shortage and compounding in 2026.

Here is the distinction this entire industry blurs. A compounded drug can be legal to dispense and still be not FDA-approved. Both things are true at once, and sellers profit from your confusion between them.

FDA approval means the exact product was tested for safety, effectiveness, and manufacturing quality. Wegovy earned that in June 2021 — the first new weight-management approval since 2014, per the FDA’s announcement. Zepbound earned it in November 2023. No compounded semaglutide or tirzepatide has ever earned it. The FDA has not reviewed a single compounded GLP-1 for safety, effectiveness, or quality.

The clinical numbers you see in ads come from the approved drugs only. Semaglutide 2.4 mg produced an average 14.9% body-weight loss over 68 weeks in the STEP 1 trial published in the New England Journal of Medicine. Tirzepatide reached up to 20.9% over 72 weeks in SURMOUNT-1. A compounded copy borrows those numbers without earning them — some copies have even used different salt forms of semaglutide, which the FDA warns are not the same active ingredient as the approved drug.

This gap has teeth. In September 2025 the FDA announced warning letters to roughly 30 telehealth companies over false or misleading compounded GLP-1 marketing. One seller, Sprout Health, was cited on September 9, 2025 for claiming its compounded GLP-1s were FDA-approved — they were not. Hims & Hers drew a letter the same day for its Hers brand, and its stock fell about 8% on the news, per third-party financial reporting. Want to know which products actually hold approval? Our GLP-1 drug list sorts every option by FDA status.

Fair question. If the shortage exception died in 2025, why do dozens of sites still sell compounded semaglutide for $89 to $199 a month?

The answer is one clause in Section 503A. The essentially-a-copy ban does not apply when a prescriber documents that a specific change — a different dose, an added ingredient like vitamin B12, a different form — makes a significant difference for that individual patient. Telehealth sellers rebuilt their entire business on that clause. That is why 2026 menus push “personalized” doses, sublingual drops, and vitamin-blended vials.

The FDA is openly skeptical. It has warned that routine tweaks made to evade the copy rule do not count as genuine personalization, and its September 2025 letters specifically flagged sellers implying their custom blends were the same as approved drugs. Then came the harder hit: on February 6, 2026, the agency announced it would restrict the raw GLP-1 ingredients feeding mass-marketed copies — naming Hims & Hers directly — and the next day the company said it would drop its compounded semaglutide pill, per CNBC reporting.

Where does that leave the personalization argument? Legally alive, commercially shrinking, and untested at scale in court. We would not bet a 12-month prepay on it surviving 2027 intact — and neither should you.

503A vs. 503B: Two Rulebooks, Two Fates

Every compounded GLP-1 comes from one of two kinds of facility, and the 2026 rules treat them very differently. About 90 seconds of jargon, worth every one.

503A pharmacy 503B outsourcing facility
Makes drugs for One named patient per prescription Bulk batches, no patient names needed
Overseen mainly by State pharmacy boards FDA directly, under cGMP rules
GLP-1 copies in 2026 Only with documented personalization Proposed for total shutdown
Typical role Custom doses, added B12, drops Was the engine of sub-$200 supply

The April 30, 2026 proposal targets the right-hand column. The FDA moved to strike semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the roster of ingredients outsourcing facilities may compound in bulk — after finding no clinical need. Comments closed June 29, 2026; a final rule is pending as we write this. If it lands, the bulk lane closes permanently.

Watch the disclosure gap while this plays out. Some sellers name their pharmacy partners and their 503A or 503B status; many disclose nothing, describing only “licensed US pharmacies,” per our review of published site terms. A seller that hides its pharmacy is asking you to take 100% of the quality risk on faith. The FDA has already documented dosing errors and adverse events requiring hospitalization with compounded GLP-1s — that is exactly the risk a named, inspectable pharmacy reduces.

State Lines Change the Answer

Federal law is only half the picture. 503A pharmacies answer to state pharmacy boards, and states have moved at very different speeds since 2025.

You can see it in the sellers’ own fine print. Noom’s compounded plans exclude Alabama, Louisiana, and Mississippi outright, per its published terms — three states where regulators or laws have made compounded GLP-1 sales untenable. Other companies disclose that certain states require a live video visit before any prescription, while a $0-extra asynchronous form review is enough elsewhere, per their published intake policies.

Practical takeaway: the same $99 vial can be legal in your state and off the menu one state over. Any telehealth checkout that never asks where you live — or ships all 50 states with zero state-specific rules — deserves your suspicion, not your card number.

What the Crackdown Means for Your Wallet

Every legal tightening since 2025 has pushed the market the same direction: fewer compounded sellers, better brand-name deals. The economics are flipping in real time.

On the brand side, manufacturer cash channels changed the math. The Wegovy pill now lists from about $149 a month through direct-pharmacy programs, and telehealth platforms like Ro sold only FDA-approved brand GLP-1s as of July 2026, per their published pricing pages. Compare that with 2024, when the only approved options were $1,000-plus pens and copies looked irresistible.

On the compounded side, prices cluster between $89 and $299 a month — but the sellers carry the legal risk we just walked through, plus wind-down risk if the 503B rule finalizes. A 12-month prepaid compounded plan is a bet that a product under active FDA restriction still ships in month 12. Run the full numbers in our semaglutide cost breakdown before you commit to either lane.

And if your budget caps near $150, the picture is genuinely workable now. Our best GLP-1 under $150 ranking found six real options at that line in 2026 — including FDA-approved medication, not just copies — once you read every renewal clause.

The Bottom Line

Are compounded GLP-1s legal in 2026? As mass-market copies: no — that ended between March and May 2025. As patient-specific prescriptions with documented clinical need: yes, for now, in most states. As FDA-approved medicine: never — not one compounded GLP-1 holds approval.

Three numbers tell you where this goes. About 30 warning letters in September 2025. Two lost injunctions in federal court. One pending rule that would close bulk compounding for good. The trend line is not subtle.

If you buy compounded anyway, buy like a skeptic: demand the pharmacy’s name and 503A/503B status, a valid prescriber review, and month-to-month billing — never a long prepay on a product regulators are squeezing. And price the approved alternative first, because at $149 a month for a Wegovy pill, the copy’s discount is thinner than it has ever been.